GM-CSF and Fosfomycin Rectal Composition for IBD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory bowel diseases (IBD) like Crohn's disease and ulcerative colitis are inadequate due to incomplete understanding of the underlying pathology, and systemic administration of GM-CSF has shown limited therapeutic potential with adverse systemic effects.
Innovation Solution
Local administration of GM-CSF compositions directly into the bowel lumen, combined with antimicrobial agents such as fosfomycin and metronidazole, to target inflammatory lesions and restore the mucosal barrier function while minimizing systemic pro-inflammatory effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic administration of GM-CSF is used to treat IBD, then therapeutic effect is improved, but adverse systemic effects increase
Solution Approach 1:
The patent divides the administration approach into local (rectal/enema) and systemic components, delivering GM-CSF specifically to the affected bowel regions rather than distributing it systemically. This segmentation allows therapeutic action at the disease site while avoiding widespread systemic exposure and associated adverse effects.
Solution Approach 2:
The invention applies GM-CSF locally to the bowel lumen through rectal administration, creating a high concentration of the drug at the target site (inflamed mucosa) while maintaining low systemic levels. This local quality approach ensures effective treatment of IBD lesions without triggering systemic pro-inflammatory responses.
2Object-affected harmful factors
If local administration of GM-CSF is used to minimize systemic effects, then adverse systemic effects are reduced, but therapeutic effectiveness may be compromised
Solution Approach 1:
Rectal administration of GM-CSF creates a localized high concentration gradient that maximizes drug availability at the inflamed mucosal sites while minimizing systemic absorption. The formulation ensures adequate local dosing for therapeutic effectiveness without achieving systemic levels that cause adverse effects.
Solution Approach 2:
The patent uses the rectal lumen and mucosal barrier as an intermediary delivery system, allowing GM-CSF to reach the affected bowel regions directly. This intermediary approach bypasses systemic circulation, delivering the drug precisely where needed while preventing the harmful systemic exposure that would otherwise occur with conventional administration routes.
3Reliability
If combination with antimicrobial agents is added to enhance therapeutic effect, then treatment efficacy is improved, but composition complexity increases
Solution Approach 1:
The patent combines GM-CSF with antimicrobial agents (such as metronidazole or ciprofloxacin) into a single rectal formulation, creating a synergistic treatment that addresses both the inflammatory component (via GM-CSF) and the infectious/microbial component (via antimicrobials) of IBD pathogenesis. This merging of therapies into one composition enhances overall treatment efficacy while simplifying the administration regimen.
Solution Approach 2:
The combined formulation serves multiple therapeutic functions simultaneously: GM-CSF promotes mucosal healing and immune regulation, while the antimicrobial agents address dysbiosis and infectious triggers. This multi-functional composition provides comprehensive IBD treatment through a single rectal administration, reducing the need for multiple separate treatments.
Data Source
AI summary
The present invention provides compositions comprising granulocyte-macrophage colony-stimulating factor and fosfomycin for the treatment, prevention or alleviation of an inflammatory bowel disease such as Crohn's disease, ulcerative colitis or necrotizing enterocolitis of newborn and premature infants by administration of the compositions into the intestinal lumen.